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A 73-days old infant of 34 weeks’ gestation was hospitalized with a co-infection of
respiratory syncytial virus (RSV) and Bordetella pertussis (BP). She required invasive
ventilation for 9 days in the context of malignant pertussis with persistent hypoxemia
and hypercapnia secondary to a leukemoid reaction. Despite an increase of white
blood cell (WBC) count up to 70 G/L and ensuing pulmonary hypertension, no
hemodynamic compromise occurred. Without clear indication for leukapheresis nor
exchange transfusion, an off-label treatment with hydroxyurea was given for 5 days with
gradual decrease of WBC count, without any complication and hospital discharge on day
29. To our knowledge, no effective therapy for malignant pertussis has been described in
the literature and complications are frequent with leukoreduction procedures. We discuss
an alternative to invasive procedures in young infants to fulfill the need to decrease rapidly
leukocyte counts in a leukemoid reaction associated with Bordetella pertussis infection.
To our knowledge, hydroxyurea has never been used in malignant pertussis but is a
well-known medication for oncologic and hematologic diseases such as acute myeloid
leukemia or sickle cell anemia. Its effects in this setting are not well understood but the
positive outcome in our patient supports the need for further studies.
Keywords: bordetella pertussis, hydroxyurea, hyperleukocytosis, leukemoid reaction, white blood cell count
BACKGROUND
Bordetella pertussis is a worldwide, human-restricted bacterium that was first isolated in 1906 by
Jules Bordet. The World Health Organization (WHO) estimates that this pathogen was found in
16 million infectious disease worldwide and caused 195,000 deaths in 2008, 95% of which occurred
in developing countries (1). In Switzerland, between 2010 and 2014, about 8,700 annual cases were
identified (declaration is mandatory in our country) despite the recommended national vaccination
program. Currently, about 30 children are hospitalized each year, mainly infants, and four pertussis
related deaths have been reported in the past 15 years (2).
Malignant pertussis, the most severe form, is characterized by major leukocytosis, refractory
hypoxemia, pulmonary hypertension and cardiopulmonary compromise, with high morbidity and
mortality. A prospective study in the United States showed a 10-fold increase in the risk of death in
the presence of leukocytosis>50 G/L. There was also a clear association between highmedian white
blood count, mechanical ventilation and pulmonary hypertension (3). In this cohort, the majority
of the patients was less than 3-month-old.
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Leukocytosis causes a hyperviscosity syndrome with
leukostasis, which can be complicated by intracranial
hemorrhages and pulmonary hypertension (4). Targeted
antibiotic therapy is the first line treatment, in combination with
supportive care (invasive ventilation, oxygenation, nutritional
support). Leukapheresis or exchange transfusion are adjunctive
therapies proposed to reduce leukocytosis and its adverse
consequences (4–6).
Hydroxyurea has been used to reduce blood counts in
several oncologic and hematologic disorders such as acute
myeloid leukemia, polycythemia, thrombocythemia and sickle
cell disease. To our knowledge, hydroxyurea has never been
used in malignant pertussis. We report the case of an infant
with malignant pertussis and leukemoid reaction treated by
hydroxyurea.
CASE PRESENTATION
Seventy-three days-old infant born prematurely at 34 1/7 weeks
of gestation with a birth-weight of 1,765 g (P 10-25) was admitted
for respiratory syncytial virus bronchiolitis with runny nose
and decreased food intake. She was vaccinated according to
Swiss recommendations (Infanrix pentavalent R©/Prevenar R©) at
2-months of age. Her parents were not vaccinated against BP.
On day 4 of hospitalization, she developed severe respiratory
distress. Chest X-ray showed a right upper lobe pulmonary
infiltrate. Blood workup revealed an elevated C - reactive
protein (CRP 210 mg/L) and hyperleukocytosis (64 G/L)
(differential blood count initially not done). Due to clinical
respiratory distress and hypercapnia, non-invasive ventilation
was started. Hypercapnia worsened despite this treatment, and
the child needed mechanical ventilation and was transferred
to our Pediatric Intensive Care Unit (PICU). Due to the
respiratory worsening associated with increasing inflammatory
parameters, a bacterial infection was suspected and intravenous
antibiotic treatment with ceftriaxone 100 mg/kg/day was started.
Subsequent workup showed a positive Streptococcus pneumoniae
antigen in urine and a positive Bordetella pertussis PCR in
the nasal sample. BP had been specifically searched due to
the severe hyperleukocytosis associated with lymphocytosis
and intravenous clarithromycin 20 mg/kg/day was added to
ceftriaxone.
The child required high ventilatory parameters and up to
100% oxygen. Despite this ventilatory support, hypercapnia
persisted. An echocardiogram showed pulmonary hypertension
but a preserved right ventricular function. Leukocytosis
first decreased probably due to fluid resuscitation and
consecutive haemodilution. On day 6, leukocytosis worsened
(Figure 1) but leukapheresis was not yet clearly indicated. As
respiratory status was not improving, we decided to introduce
hydroxyurea (Litalir R©) at an initial dosage of 10 mg/kg/day.
This treatment was increased gradually up to 30 mg/kg/day with
a subsequent decrease in leucocytes count (Figure 1). On day
Abbreviations: BP, Bordetella pertussis; WBC, white blood cell; ECMO,
extracorporeal membrane oxygenation; RSV, respiratory syncytial virus; PICU,
pediatric intensive care unit.
10, leucocytes decreased to 34 G/L and hydroxyurea treatment
was discontinued to avoid iatrogenic leukopenia (Table 1).
Simultaneously, respiratory condition improved, and the child
could be extubated on day 13. Both antibiotics were stopped
after 7 days of treatment. Oxygen therapy was required until
day 25. The child was discharged home on day 29 without any
complications.
DISCUSSION
Pertussis and Leukemoid Reaction
This patient presented with a severe form of malignant pertussis
and secondary leukemoid reaction. This hematologic reaction,
occurring in the context of BP infection, was first described more
than a century ago and has a diagnostic value since 1898 (7).
Infants typically show this kind of reaction characterized byWBC
count over 50 G/L with a marked lymphocytosis. This reaction
is different from hyperleukocytosis occurring specifically in an
oncological context and defined by WBC count greater than 100
G/L in the peripheral blood (8).
Leukemoid reaction is caused by BP toxin, but the specific
mechanisms are not yet clearly understood. One of the proposed
mechanisms might be the inhibition of lymphocyte extravasation
to the infected site and facilitation of lymphocyte migration
from the spleen and the bone marrow, resulting in leukocytosis.
Phenotypic analyses show that pertussis leukocytosis consists
of an expansion of normal naïve cells population rather than
proliferation of activated cells (7). Another effect of pertussis
toxin is the inactivation of many G proteins involved in cellular
regulatory mechanisms. Some of these G proteins have protective
effects on the cardiorespiratory system and their inactivation
explains the rapid increase in heart and respiratory rate seen in
these situations. One hypothesis is that leukocytosis is the marker
of toxin activity, and inhibition of G proteins in the heart and
lung may be the cause of death (9).
Several studies have shown a significant association between
leukemoid reaction and fatal evolution, either regarding the
absolute value of leukocytosis or its rate of progression (3,
9–14). Although most agree that poor prognosis is highly
correlated with leukocytosis >100 G/L, a negative impact on
survival of leukocyte counts >55 G/L has also been shown
(15). Other factors of poor prognosis identified are low birth
weight, gestational age, seizure during infection and pulmonary
hypertension (3). The patient we describe meets several of these
factors, namely: low birth weight, prematurity and pulmonary
arterial hypertension.
Urgent Need to Decrease Leukocytes
Count
Hyperviscosity and leukostasis induced by the increase of
circulating leucocytes leads to potential major complications such
as intracranial bleeding and pulmonary failure with hypoxia and
hypercapnia. Most post-mortem analyses reveal the presence of
thrombi in venous, arterial and lymphatic pulmonary vessels
(4, 16–19). In this context, the development of pulmonary arterial
hypertension seems to be multifactorial: increased pulmonary
resistance due to hyperviscosity in the setting of leukocytosis
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FIGURE 1 | Evolution of WBC during the hospitalization and representation of the different therapies. NIV, Non-Invasive Ventilation.
TABLE 1 | Differential blood count and platelets during PICU stay.
Leukocytes
G/L
Lymphocytes
G/L (%)
Neutrophils
G/L (%)
Bands G/L
(%)
Monocytes
G/L (%)
Eosinophils
G/L (%)
Basophils
G/L (%)
Platelets
G/L
Day 4 63.8 28.7 (45) 30.6 (48) 6.4 (10) 1.3 (2) 0.6 (1) 0.0 (0) 874
Day 5 51.2 25.6 (50) 20.0 (39) 0.0 (0) 3.1 (6) 0.0 (0) 0.5 (1) 857
Day 6 49.0 25.5 (52) 21.1 (43) 0.0 (0) 1.5 (3) 0.0 (0) 0.0 (0) 892
Day 7 69.7 30.7 (44) 35.5 (51) 1.4 (2) 2.8 (4) 0.7 (1) 0.0 (0) 895
Day 8 42.3 20.7 (49) 19.0 (45) 0.0 (0) 2.1 (5) 0.4 (1) 0.0 (0) 701
Day 9 47.9 23.5 (49) 22.5 (47) 0.0 (0) 1.4 (3) 0.0 (0) 0.0 (0) 739
Day 10 33.9 18.6 (55) 13.6 (40) 0.3 (1) 1.7 (5) 0.3 (1) 0.0 (0) 656
Day 11 32.7 18.0 (55) 10.8 (33) 0.0 (0) 1.3 (4) 0.3 (1) 0.0 (0) 627
Day 12 31.2 19.0 (61) 8.7 (28) 0.0 (0) 2.2 (7) 0.9 (3) 0.0 (0) 597
Day 13 32.1 19.3 (60) 11.2 (35) 0.6 (2) 1.3 (4) 0.0 (0) 0.0 (0) 628
Day 14 40.9 22.1 (54) 16.8 (41) 0.0 (0) 1.6 (4) 0.4 (1) 0.0 (0) 664
Day 15 38.5 15.4 (40) 19.3 (50) 0.0 (0) 3.9 (10) 0.0 (0) 0.0 (0) 648
Day 18 25.8 11.9 (46) 11.4 (44) 0.0 (0) 1.8 (7) 0.8 (3) 0.0 (0) 651
and thrombi; vasoconstriction induced by hypoxia in young
children whose pulmonary vascular reactivity is increased; and,
as mentioned above, the direct effect of the toxin on heart
and lungs (14, 19). Acting on leukocytosis is essential to
limit the hemodynamic consequences and the use of cardiac
and respiratory support, such as extra-corporeal membrane
oxygenation (ECMO), which has a high mortality rate without
concomitant leukoreduction.
Two way of managing hyperleukocytosis, beside
chemotherapy, are currently used for urgent cytoreduction
in severe or symptomatic cases: leukapheresis and exchange
transfusion. Leukapheresis is the treatment of choice in cases
of hyperviscosity with hemodynamic impact, but there are
some limitations of this technique: difficult vascular access in
young children, risks associated with anticoagulation, poor
experience or unavailability of the procedure (8). In a case series
of 102 children with acute leukemia and hyperleukocytosis
treated with leukapheresis, Abla et al. described a complication
rate of 86%. Most complications in this study were metabolic
disorders, hemodynamic instability and coagulopathy (20).
Exchange transfusion is a useful and safer alternative, since it
is widely used for other diseases. The complications are the
same as for any transfusions (4). Several studies have shown a
quick improvement of hypoxemia following a leukodepletion
therapy in pertussis infection, whether by leukapheresis or
exchange transfusion. The study of Rowlands et al. demonstrated
the benefit of fast leukoreduction strategy in 10 patients
younger than 3 months old with hyperviscosity syndrome
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during pertussis infection and with consecutive cardiovascular,
pulmonary and neurological repercussions (21). Between 2005
and 2009, five patients underwent leukapheresis under ECMO
while five others only exchange transfusion. The global survival
rate was 90%. A similar study between 2001 and 2004 of 9
patients, including 6 treated with ECMO, without any leukocyte
reduction technique, showed survival of 55% (21). Several other
small case series reporting experience of exchange transfusion in
malignant pertussis showed survival rates between 54 and 92%
(4, 22–25). Some authors point out that exchange transfusion
should be preferred over leukodepletion methods because it
simultaneously removes pertussis toxin (9).
An Alternative to Invasive Procedures?
Our patient had a respiratory failure with refractory hypoxemia
and hypercapnia, despite a high ventilatory support, pulmonary
hypertension without cardiac repercussion and no neurologic
symptoms. Even if the WBC count increased in a worrying way,
it remains under 100 G/L. In the absence of clear criteria in the
literature to arbitrate for leukapheresis and considering the risks
of this procedure, we sought an alternative therapy to reduce
leukocytosis. By analogy with its use in oncological context, an
off-label treatment with hydroxyurea (Litalir R©) was introduced.
Hydroxyurea, or hydroxycarbamide, is an old drug, whose
inhibitory effects on leucocytes is known since the end of
the 1860s. Since the 1960s, the efficacy of hydroxyurea on
hyperleukocytosis associated with acute myeloid leukemia is
well described, especially on the rapid reduction of blast cells,
thus preventing the complications of hyperleukocytosis (26, 27).
Its use has spread to other types of cancer (carcinoma of the
head or the neck), and to some non-neoplastic pathologies
such as HIV infection or sickle cell anemia. Hydroxyurea is an
antiproliferative medication interfering with DNA synthesis. The
cytostatic effect is driven by ribonucleotide reductase inhibition
and thus cell cycle arrest in the absence of sufficient nucleotide
pools (28). Absorption through the digestive system is rapid
with plasma peaks reached within 1 h. Hydroxyurea accumulates
particularly in blood cells, especially the white line. The passage
through the blood-brain barrier is easy. Entry into cells is
a passive phenomenon with rapid balancing of concentration
between different tissues and blood (28, 29).
In the sickle cell anemia, hydroxyurea improves the
pathophysiology and seems to be the only treatment with proven
benefits. This treatment reduces acute complications, such as
painful vaso-occlusive events and acute thoracic syndrome, as
well as need for blood transfusions and hospitalizations. The
survival in adult and child is also improved (30). In this case,
hydroxyurea increases production of fetal hemoglobin via nitric
oxyde production and decreases adherence of red blood cell to
the vascular endothelium (31).
In HIV infection, hydroxyurea has an inhibitory effect on
viral replication. Benito et al. studied the effect in vitro on T
cell proliferation and activation. A dose-dependent effect on the
proliferation of T cells, with a decreased average number of
mitoses was shown. An impact on the expression of the different
markers of T cell activation was also demonstrated (32).
This mechanism of action may explain the potential benefit
of hydroxyurea to decrease lymphocytosis in whooping cough,
which mainly increases lymphocytes. Nevertheless, as previously
discussed, leukocytosis in pertussis is an expansion of naive cells
and not a proliferation of new cells. Another mechanism causing
the cell-killing effect of hydroxyurea would be the production of
oxidative stress and the induction of a cessation of cytokinesis, as
some studies seem to show (31). None of the known mechanisms
of action of hydroxyurea alone seems to counteract the effects of
pertussis toxin, but many of these mechanisms may be involved.
Although the action of hydroxyurea on leukocytosis caused by
the pertussis toxin is not yet understood, its effect in our patient
was positive. We found a resolution of the leukemoid reaction
after 5 days of treatment without developing lysis syndrome
or other recognizable adverse reactions. We hypothesize that
part of leukocytosis seen in malignant pertussis may be due to
overproduction of new white cells which is then decreased with
hydroxyurea treatment. Nevertheless, given that 50% patients
spontaneously recover with supportive therapy alone, the current
outcome of the patient maybe is not the consequence of
hydroxyurea therapy.
The speculative risk of hydroxyurea treatment is the
consecutive myelosuppresion, leukopenia, thrombocytopenia
and anemia but there is no clear evidence in the literature of
severe complications with standard dosage (between 10 and 30
mg/kg/day).
New experimental therapies, such as monoclonal antibodies
against pertussis toxin or other targets to reduce pulmonary
damage are under investigation. These approaches seem to be
promising on mice models but need further evaluation (33, 34).
CONCLUDING REMARKS
Currently there is no effective treatment for malignant
pertussis. Management of these patients is mainly supportive.
Leukapheresis, exchange transfusion and ECMO therapy
have been associated with high mortality and complications
(17). Malignant pertussis is an old, well-known disease and
perhaps an old drug like hydroxyurea may be a new treatment
strategy in this setting. This non-invasive approach needs
further studies, but hydroxyurea used preventively may
avoid heart failure or neurological symptomatology and the
subsequent need of for invasive leukoreduction procedures and
associated complications.
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